Ra Pharmaceuticals (RARX) Stock Price, News & Analysis

Company Overview

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $47.99 to $47.99
• 50-Day Range: $47.99 to $48.00
• 52-Week Range: $19.64 to $48.02
• Volume: 30,200 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $2.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RARX Stock Analysis - Frequently Asked Questions

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) issued its earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16.

When did Ra Pharmaceuticals IPO?

Ra Pharmaceuticals (RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

What other stocks do shareholders of Ra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Cos (BHC) and Galmed Pharmaceuticals (GLMD).

Company Calendar

• Last Earnings: 2/27/2020
• Today: 8/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RARX
• CIK: 1481512
• Web: www.rapharma.com
• Phone: 617-401-4060
• Fax: N/A
• Employees: 72
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$102.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -44.61%
• Return on Assets: -41.60%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 14.78
• Quick Ratio: 14.79

Sales & Book Value

• Annual Sales: $3 million
• Price / Sales: 757.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.56 per share
• Price / Book: 8.63

Miscellaneous

• Outstanding Shares: 47,329,000
• Free Float: N/A
• Market Cap: $2.27 billion
• Optionable: Optionable
• Beta: 1.05